Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 double-blind trial of zasocitinib vs deucravacitinib in moderate-to-severe plaque psoriasis
jRCT2011250014Phase 3Completed
- Sponsor
- Takeda
- Start
- Jul 2025
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in plaque psoriasis comparing Zasocitinib arm with Deucravacitinib arm (2 arms). Primary endpoint: PASI-100 response at Week 16. Started Jul 2025; status: completed.
02
Drugs
zasocitinibdeucravacitinib
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on jRCT2011250014.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011250014.